Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia

BALTACI, Davut; ÖNCÜ, Mustafa öncü; AYDIN, Ibrahim; türkyılmaz, serdar

Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia

İbrahim AYDIN, (Rize Eğitim ve Araştırma Hastanesi, Genel Cerrahi Kliniği, Rize, Türkiye)

Davut BALTACI, (Düzce Üniversitesi, Tıp Fakültesi, Aile Hekimliği Anabilim Dalı, Düzce, Türkiye)

Serdar TÜRKYILMAZ, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, Trabzon)

Mustafa ÖNCÜ (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, Trabzon)

Düzce Tıp Fakültesi Dergisi

7 1

Yıl: 2012 Cilt: 14 Sayı: 1 Sayfa Aralığı: 1 - 5 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia

Öz:

Giriş: Mastalji meme ağrısı olup klinik olarak siklik ve siklik olmayan şeklinde sınıflandırılır. Siklik mastalji mastaljilerin yaklaşık %60’ını kapsar. Siklik mastaljiler en sık 20 ve 30 yaşlarda görülür ve genellikle tedaviye iyi cevap verir. Amaç: Vastus Agnus Castus preparasyonunun (VAC) mastalgi ve hiperprolaktinemi üzerine olan etkinliğinin araştırılması amaçlandı. Metot: Araştırma prospektif ve palsebo kontrollü klinik çalışma olarak yapıldı. Hastalar gruplara ayrılmadan önce her hastadan prolaktin seviyesine bakıldı. Hastalar gruplara ayrıldıktan sonra her hastaya tedavi öncesi VAS uygulandı. Grub 1 siklik mastaljisi ve hiperprolaktinemisi olan hastalardan oluştu. Bu hastalara VAC (agnucaston) başlandı. Grup 2 siklik mastaljisi ve normal prolaktin seviyesi olan ve meloksikam 15 mg/gün başlanan hastalardan oluşmuştur. Placebo grubu mastaljisi olan ve prolaktin seviyesi normal olan hastalardan oluştu. 3 aylık tedavi sonrası her hastaya VAS ve grup 1 için prolactin seviyesine bakıldı. Sonuçlar: Toplam 19–54 yaş arası 95 hastanın analizi yapıldı. VAC alan grupta mastaljinin yoğunluğu plasebo grubundan anlamlı ölçüde azaldığı gözlendi (p<0,0001). VAS skoruna ilaveten, prolaktin seviyesinde tedavi öncesine göre anlamlı azalma tespit edildi (p <0.0001). Sonuç olarak, VAC preperasyonunun mastalji ve hiperprolaktinemi tedavisinde iyi tolerabilite ile birlikte etkin olduğunu bulduk.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Siklik mastaljili hastaların tedavisinde vitex agnus castus preperatının meloksikam ve plasebo ile karşılaştırılması

Öz:

Background: Mastalgia is classified as cyclic and non-cyclic. Cyclical one constitutes approximately 60-70% of mastalgia. It is seen between 2 to 3 decades of age, and it usually responds to treatment. Objectives: To compare efficacy of vitex agnus castus (VAC) preparation with meloxicam and placebo in treatment of mastalgia. Methods: The study was designed as prospective and placebo-controlled clinical trial. Three groups were constituted. Before grouping, prolactin level was tested for every patient. The group1 enrolled the patients with cyclical mastalgia and high level prolactin. VAC was administered to patients from study group1. The second group enrolled the patients with cyclical mastalgia along with normal prolactin level, and to which meloxicam was given. Third group was placebo group, and placebo was applied. Before treatment, VAS (Visual analogue scale) scoring was applied to every patient. Prolactin level was tested for patients from group 1. After 3 months of study, VAS scoring was applied to every patient, but only prolactin levels were reevaluated in patients from group1. Results: 95 patients were analyzed; enrolling women aged 19 to 54 years. Intensity of mastalgia diminished in VAC group 1, 2 more than in placebo group (p<0.0001). In addition to VAS scoring, prolactin level in group 1 after treatment was significantly reduced, comparing with before treatment (p<0.0001). In conclusion, we found that VAC preparation was effective in the treatment of mastalgia and hyperprolactinemia, with good tolerability.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Plu-Bureau G, Thalabard JC, Sitruk-Ware R, et al. Mastalgia. J Obstet Gynaecol Can. 2006;28(1):49–71.
2. Antonio VM, Frederick MD. Clinical management of breast pain: A review. Obstet Gynecol Surv. 2002;57(7):451-61.
3. Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: Prevelance and associated health and behaviorioral factors. J Psyhosom Obstet Gynecol. 2001;22:71-6.
4. Tavaf-Motamen H, Ader DN, Browne MW, et al. Clinical evaluation of mastalgia. Arch Surg. 1998;133(2):211-3.
5. Plu-Bureau G, Thalabard JC, Sitruk-Ware R, et al. Cyclical mastalgia as a marker of breast cancer susceptibility: Results of a case-control study among French women. British Journal of Cancer. 1992;65(6):945-9.
6. Halaska M, Beles P, Gorkow C, et al. Chaste tree (Vitex Agnus Castus) Pharmacology and Clinical Indications. Breast. 1999;8(4):175-81.
7. Gorkow C, Wuttke W, März RW. Effectiveness of vitex agnus castus preparations. Wien Med Wochenschr. 2002;152(15- 16):364-72.
8. Carmichael AR. Can Vitex Agnus Castus be used for the treatment of mastalgia? What is the current Evidence? Evid Based Complement Alternat Med. 2008;5(3):247-50.
9. Holland PA, Gateley CA. Drug therapy of mastalgia. What are the options? Drugs. 1994;48(5):709-16.
10.Bilichert-Toft M, Watt-Boolsen S. Clinical approach to women with severe mastalgia and therapeutic posibilities. Acta Obstet Gynecol Scand Suppl. 1984;123:185-8.
11.Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus)--pharmacology and clinical indications. Phytomedicine. 2003;10(4):348-57.
12.Daniele C, Thompson Coon J, Pittler MH, et al. Vitex agnus castus: a systematic review of adverse events. Drug Saf. 2005;28(4):319-32.
13.Gataley C. A, Mansel R.E. Management of the painful and nodular breast. British Medical Bulletin. 1991;47(2):284-94.
14.Gatalay C, Mansel RE, Maddox PR, et al. Mastalgia refractory to drug treatment. British Journal of Surgery. 1990;77:1110- 12.
15.Tschudin S, Huber R. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: Results of a placebo-controlled double-blind study. Forsch Komplementarmed Klass. Naturheilkd. 2000;7(3):162-4.
16.Millet AV, Dirbas FM. Clinical management of breast pain: a review. Obstet Gynecol Surv. 2002;57(7):451–61.
17.Halaska M, Beles P, Gorkow C, et al. Treatment of cyclical mastalgia with a solution containing a Vitex Agnus Castus extract: Results of a placebo-controlled double-blind study. Breast. 1999;8(4):175-81.
18.van Die MD, Burger HG, Teede HJ, et al. Vitex agnus-castus (Chaste-Tree/Berry) in the treatment of menopause-related complaints. Altern Complement Med. 2009;15(8):853–62.
19.Sliutz G, Speiser P, Schultz AM, Spona J, et al. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res. 1993; 25(5):253–5.
20.Parsay S, Olfati F, Nahidi S, et al. Therapeutic Effects of Vitamin E on cyclic mastalgia. Breast Journal. 2009;5(5):510- 4.
21.Denneheny CE. The Use of Herbs and Dietary Supplements in Gynecology: An Evidence- Based Review. J. of Midwifery Womens Health. 2006;51(6):402-9.
22.Mansel RE. ABC of Breast Diseases. BMJ. 1994;309:866-8.
23.Khan SA, Apkarian AV. The characteristics of cyclical and non-cyclical mastalgia: a prospective study using a modified McGill Pain Questionnaire. Breast Cancer Research and Treatment. 2002;75:147-57.

APA	AYDIN I, BALTACI D, türkyılmaz s, ÖNCÜ M (2012). Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia. , 1 - 5.
Chicago	AYDIN Ibrahim,BALTACI Davut,türkyılmaz serdar,ÖNCÜ Mustafa öncü Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia. (2012): 1 - 5.
MLA	AYDIN Ibrahim,BALTACI Davut,türkyılmaz serdar,ÖNCÜ Mustafa öncü Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia. , 2012, ss.1 - 5.
AMA	AYDIN I,BALTACI D,türkyılmaz s,ÖNCÜ M Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia. . 2012; 1 - 5.
Vancouver	AYDIN I,BALTACI D,türkyılmaz s,ÖNCÜ M Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia. . 2012; 1 - 5.
IEEE	AYDIN I,BALTACI D,türkyılmaz s,ÖNCÜ M "Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia." , ss.1 - 5, 2012.
ISNAD	AYDIN, Ibrahim vd. "Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia". (2012), 1-5.

APA	AYDIN I, BALTACI D, türkyılmaz s, ÖNCÜ M (2012). Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia. Düzce Tıp Fakültesi Dergisi, 14(1), 1 - 5.
Chicago	AYDIN Ibrahim,BALTACI Davut,türkyılmaz serdar,ÖNCÜ Mustafa öncü Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia. Düzce Tıp Fakültesi Dergisi 14, no.1 (2012): 1 - 5.
MLA	AYDIN Ibrahim,BALTACI Davut,türkyılmaz serdar,ÖNCÜ Mustafa öncü Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia. Düzce Tıp Fakültesi Dergisi, vol.14, no.1, 2012, ss.1 - 5.
AMA	AYDIN I,BALTACI D,türkyılmaz s,ÖNCÜ M Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia. Düzce Tıp Fakültesi Dergisi. 2012; 14(1): 1 - 5.
Vancouver	AYDIN I,BALTACI D,türkyılmaz s,ÖNCÜ M Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia. Düzce Tıp Fakültesi Dergisi. 2012; 14(1): 1 - 5.
IEEE	AYDIN I,BALTACI D,türkyılmaz s,ÖNCÜ M "Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia." Düzce Tıp Fakültesi Dergisi, 14, ss.1 - 5, 2012.
ISNAD	AYDIN, Ibrahim vd. "Comparison of vitex agnus castus with meloxicam and placebo in treatment of patients with cyclical mastalgia". Düzce Tıp Fakültesi Dergisi 14/1 (2012), 1-5.